Safeguarding the blood supply is critical. Pathogen reduction provides you that added measure of security against disease-causing agents, including viruses, parasites, bacteria and white blood cells.

Naturally, you want a partner you can trust.

The Mirasol® Pathogen Reduction Technology (PRT) System uniquely uses the properties of riboflavin (vitamin B2) and ultraviolet light to reduce the infectious pathogen load and inactivate residual white blood cells in blood products.*

The Mirasol system renders pathogens harmless by using a non-mutagenic, non-toxic method, eliminating the need to remove phototoxic agents prior to transfusion – making your treated blood products immediately available to treat patients.

Using a single, integrated system for platelets and plasma, Terumo BCT’s proprietary process delivers:

SAFETY | EFFICACY | SIMPLICITY

*The Mirasol system is approved for blood in platelets and plasma and is under development for the treatment of whole blood.
Safeguarding the blood supply is critical. Pathogen reduction provides you that added measure of security against disease-causing agents, including viruses, parasites, bacteria and white blood cells.

Naturally, you want a partner you can trust. The Mirasol™ Pathogen Reduction Technology (PRT) System uniquely uses the properties of riboflavin (vitamin B2) and ultraviolet light to reduce the infectious pathogen load and inactivate residual white blood cells in blood products.*

The Mirasol™ system renders pathogens harmless by using a non-mutagenic, non-toxic method, eliminating the need to remove photochemical agents prior to transfusion – making your treated blood products immediately available to treat patients.

Using a single, integrated system for platelets and plasma, Terumo BCT’s proprietary process delivers:

SAFETY | EFFICACY | SIMPLICITY

*The Mirasol™ system is under development in Europe for platelets and plasma and is under development for the treatment of whole blood.
MIRASOL PRT IS THE OBVIOUS CHOICE FOR PATHOGEN REDUCTION AND PLASMA FOR PLATELETS

YOUR SYSTEM FOR PLATELETS AND PLASMA

MIRASOL PRT IS THE OBVIOUS CHOICE FOR PATHOGEN REDUCTION

Safety established

Mirasol-treated components have been shown to be safe for transfusion recipients as well as for those who handle blood products.

- Mirasol-treated platelet additive solution (PAS) may need to be added after illumination to platelet concentrates with reduced plasma content to ensure adequate storage conditions for up to 5 days

- Mirasol-treated FFP preserves levels of coagulants and anticoagulants that meet the Council of Europe guidelines for untreated FFP

- Mirasol-treated platelets in patients receiving Mirasol-treated platelets system in a well-controlled patient trial

No adverse events were attributed to the use of Mirasol-treated platelet products or to the use of the Mirasol PRT system in a well-controlled patient trial

Efficacy maintained

Reduce pathogen load while providing quality platelets and fresh frozen plasma (FFP).

- The MIRASOL system that confirmed its increased need for platelets on_need from transfusions in patients receiving Mirasol treated platelets

- This also showed improved CoI increments (CoI) remained stable throughout the multiple concentrations of Mirasol treatment.

- Mirasol-treated FFP pass all levels of coagulants and anti-coagulants that meet the Journal of transfusion science for automated FFP

Simplicity by design

Easy to learn. Easy to operate. Flexible. Limited handling and minimal product loss with the Mirasol process help keep complications of transfusion to a minimum.

- Mirasol-treated components have been shown to be safe for transfusion recipients as well as for those who handle blood products.

- Mirasol-treated platelet additive solution (PAS) may need to be added after illumination to platelet concentrates with reduced plasma content to ensure adequate storage conditions for up to 5 days.

- Mirasol-treated FFP preserves levels of coagulants and anticoagulants that meet the Council of Europe guidelines for untreated FFP.

REFERENCES

THE MIRASOL SYSTEM IS DESIGNED TO BE EFFECTIVE AGAINST A BROAD RANGE OF PATHOGENS WHILE STILL MAINTAINING THE QUALITY OF ANPHILLES AND WHOLE BLOOD-DERIVED BLOODED PRODUCTS. PERFORMANCE DEMONSTRATED AGAINST:

- **VIRUSES**: Enveloped and non-enveloped
- **BACTERIA**: Gram-negative and gram-positive
- **PLAQUE FORMERS**: **WHITE BLOOD CELLS (WBCS)**
- Inactivation of HIV in donated blood products may reduce biochemical complications of transfusion

Safety established

- Mirasol-treated components have been shown to be safe for transfusion recipients as well as for those who handle blood products.
- No adverse reactions have been observed in preclinical or clinical studies.
- The MIRASOL system has been demonstrated through extensive toxicology testing.
- No adverse events were attributed to the use of this isolated patient products or to the use of the MIRASOL system in a well-controlled patient trial.

Efficacy maintained

- Reduction in pathogen levels without causing platelet and red blood cell transfusion problems.
- Reduction of HIV and HCV in donated blood, as well as in units transfused.
- Reduction of iron overload in transfused patients.
- White blood cell (WBC) reduction and inactivation of WBCs in donated blood.
- Reduction of HIV and HCV in donated blood, as well as in units transfused.
- Reduction of iron overload in transfused patients.
- White blood cell (WBC) reduction and inactivation of WBCs in donated blood.
- Reduction of HIV and HCV in donated blood, as well as in units transfused.
- Reduction of iron overload in transfused patients.
- White blood cell (WBC) reduction and inactivation of WBCs in donated blood.

Simplicity by design

- Easy to use. Easy to operate. One-handed handling and minimal product loss with the Mirasol process help keep your operations efficient. In addition, a fully integrated data capture and reporting software system allows accurate reporting and simplified data management.

REFERENCES

THE MIRASOL SYSTEM IS DESIGNED TO BE EFFECTIVE AGAINST A BROAD RANGE OF PATHOGENS. WHILE STILL MAINTAINING THE QUALITY OF ANTISSIEGE AND WHOLE BLOOD-DERIVED BLOOD PRODUCTS. PERFORMANCE DEMONSTRATED AGAINST:

- **Bacteria**: Developed and non-enzymatic**
- **Viruses**: Gain-negative and gain-positive**
- **Protozoa**

Safety established

Mirasol-treated components have been shown to be safe for transfusion recipients as well as for those who handle blood products.

- **Riboflavin and its photoproducts are already present in human blood and do not need to be removed from blood prior to transfusion**
- **No adverse events were attributed to the use of this marketed platelet product or to the use of the Mirasol PRT system**
- **No adenosine triphosphate (ATP) was detected in studies assessing ATP levels in platelet concentrates**
- **Ruminant hemoglobin**

Efficacy maintained

Reduce pathogen load while providing quality platelets and fresh frozen plasma (FFP).

- **The MIRASOL system that confirmed increased levels of platelet or blood component transfusions is a modest which Mirasol treated platelets**
- **This process has been shown to be effective in reducing the levels of various pathogens in blood products**
- **Mirasol-treated FFP has been shown to be effective in reducing the levels of various pathogens in blood products**

Simplicity by design

Easy to learn. Easy to operate. Flexibility. Limited handling and minimal product loss with the Mirasol process help keep your operations efficient. In addition, our fully integrated data capture and dosage software system, the Mirasol Management ensures accurate reporting and simplified data management.

REFERENCES

Unlocking the Potential of Blood

The Mirasol system has received the CE mark for platelets and plasma and is under development for the treatment of whole blood.

MIRASOL®
PATHOGEN REDUCTION TECHNOLOGY SYSTEM

Safeguarding the blood supply is critical. Pathogen reduction provides you that added measure of security against disease-causing agents, including viruses, parasites, bacteria and white blood cells.

naturally, you want a partner you can trust.

The Mirasol pathogen reduction technology (PRT) system uniquely uses the properties of riboflavin (vitamin B2) and ultraviolet light to reduce the infectious pathogen load and inactivate residual white blood cells in blood products.

The Mirasol system renders pathogens harmless by using a non-mutagenic, non-toxic method, eliminating the need to remove photochemical agents prior to transfusion – making your treated blood products immediately available to treat patients.

Using a single, integrated system for platelets and plasma, Terumo BCT's proprietary process delivers:

S\nafety       |       e\nff\ncy       |       S\nIMPLI\ncy

©2012 Terumo BCT, Inc. / PN 306690232

Unlocking the Potential of Blood

The Mirasol PRT system can help you provide safer blood products today. Contact your Terumo BCT sales representative or visit TERUMOBCT.COM for additional information.

short.name@terumobct.com

Terumo BCT, Inc.
10811 West Collins Ave.
Lakewood, Colorado 80215-4440

Phone: +1.303.239.2399
Fax: +1.303.239.2399

Terumo BCT Europe, Middle East and Africa
Ikariaaslaan 41
1930 Zaventem, Belgium
Phone: +32.2.715.05.90
Fax: +32.2.721.07.70

Terumo BCT (Asia Pacific) Ltd.
Room 3903-3903A, 39/F
CE Tower, Windsor House
311 Gloucester Road
Causeway Bay, Hong Kong
Phone: +852.2283.0700
Fax: +852.2576.1311

Terumo BCT Latin America
Juncal 1311 4th Floor
C1062ABO Buenos Aires
Argentina
Phone: +54.11.5530.5200
Fax: +54.11.5530.5201
Safeguarding the blood supply is critical. Pathogen reduction provides you that added measure of security against disease-causing agents, including viruses, parasites, bacteria and white blood cells.

Naturally, you want a partner you can trust.

The Mirasol Pathogen Reduction Technology (PRT) System uniquely uses the properties of riboflavin (vitamin B2) and ultraviolet light to reduce the infectious pathogen load and inactivate residual white blood cells in blood products.*

The Mirasol system renders pathogens harmless by using a non-mutagenic, non-toxic method, eliminating the need to remove photochemical agents prior to transfusion – making your treated blood products immediately available to treat patients.

Using a single, integrated system for platelets and plasma, Terumo BCT’s proprietary process delivers:

**SAFETY | EFFICACY | SIMPLICITY**

*The Mirasol system is not yet approved for platelets and plasma and is under development for the treatment of whole blood.